Back to glossary
Therapeutics

Dasatinib + Quercetin (D+Q)

Reviewed by

D+Q is one of the most studied senolytic combinations: dasatinib (a tyrosine-kinase-inhibitor cancer drug) plus quercetin (a flavonoid), given intermittently and designed to selectively eliminate or reduce senescent-cell burden. Preclinical studies show improvements in physical function and tissue health in aged mice. Human data are limited to small pilot trials in IPF, diabetic kidney disease, and frailty, which have shown reductions in senescence markers; efficacy as an anti-aging therapy remains unproven and use is off-label.

Sources

  1. Justice JN, Nambiar AM, Tchkonia T et al.. (2019). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. *EBioMedicine*doi:10.1016/j.ebiom.2018.12.052
  2. Hickson LJ, Langhi Prata LGP, Bobart SA et al.. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. *EBioMedicine*doi:10.1016/j.ebiom.2019.08.069